TEC broadens SpO2 capabilities and courts potential buyers
This article was originally published in Clinica
Following the success of its Lightman Pulse oximetry sensor tester, South Wales company TEC is taking the technology further to develop a noninvasive blood spectrometry system that calibrates itself to the sensor and the patient. At the same time, the company is seeing more interest from international partners. Ashley Yeo went to Wales to find out what stage the company is at
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.